首页> 外文OA文献 >Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study

【2h】

Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study

机译：Neoadjuvant每周紫杉醇和卡铂与曲妥珠单抗和Pertuzumab在Her2阳性乳腺癌中：棕色大学肿瘤学研究组（Bruog）研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
M. L. Lopresti; J. J. Bian; B. J. Sakr; R. S. Strenger; R. D. Legare; M. Fenton; S. M. Witherby; D. S. Dizon; S. V. Pandya; A. R. Stuckey; D. A. Edmondson; J. S. Gass; C. M. Emmick; T. A. Graves; M. Cutitar; A. J. Olszewski; W. M. Sikov;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study [J] . Lopresti M. L., Bian J. J., Sakr B. J., Breast cancer research and treatment. . 2021,第1期

机译：Neoadjuvant每周紫杉醇和卡特劳替纳布和Pertuzumab在Her2阳性乳腺癌中的紫荆花素：棕色大学肿瘤学研究组（Brueg）研究
2. Neoadjuvant weekly paclitaxel (wP) and carboplatin (Cb) with trastuzumab (T) and pertuzumab (P) in HER2-positive breast cancer (H plus BC): A Brown University oncology group (BrUOG) study [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Neoadjuvant每周紫杉醇（WP）和卡铂（CB）与曲妥珠单抗（T）和Hertuzumab（P）在Her2阳性乳腺癌（H Plus BC）中：棕色大学肿瘤组（Bruog）研究
3. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. [J] . Sikov WM, Dizon DS, Strenger R Journal of Clinical Oncology . 2009,第28期

机译：布朗大学肿瘤学小组研究：每4周一次卡铂和每周紫杉醇联合或不联合曲妥珠单抗，在侵袭性II至III期乳腺癌中频繁发生病理完全缓解：布朗大学肿瘤学小组研究。
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. A randomized controlled phase II trial of neoadjuvant ado-trastuzumab emtansine lapatinib and nab-paclitaxel versus trastuzumab pertuzumab and paclitaxel in HER2-positive breast cancer (TEAL study) [O] . Tejal A. Patel, Joe E. Ensor, Sarah L. Creamer, 2019

机译：HER2阳性乳腺癌的新辅助药物阿托曲妥珠单抗坦帕尼和纳布-紫杉醇与曲妥珠单抗帕妥珠单抗和紫杉醇的II期随机对照对照试验（TEAL研究）
7. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer [O] . 2017

机译：NeoSphere研究的生物标志物分析：帕妥珠单抗，曲妥珠单抗和多西他赛与曲妥珠单抗加多西他赛，帕妥珠单抗加曲妥珠单抗或帕妥珠单抗加多西他赛对HER2阳性乳腺癌的新辅助治疗

Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study

著录项

引文网络

相似文献

相关主题

期刊订阅